!!Projects per year
Vingerafdruk
Verdiep u in de onderzoeksgebieden waarop Iris Dirven actief is. Deze onderwerplabels komen uit het werk van deze persoon. Samen vormen ze een unieke vingerafdruk.
- 1 Soortgelijke profielen
Samenwerkingen en hoofdonderzoeksgebieden uit de afgelopen vijf jaar
Recente externe samenwerking op landen-/regioniveau. Duik in de details door op de stippen te klikken of
Projecten
- 1 Afgelopen
-
AIIFUND147: Visiting Research Agreement Melanoma Therapies
Neyns, B. (Administrative Promotor) & Dirven, I. (PI (Promotor, Principal Investigator))
1/05/25 → 30/06/25
Project: Fundamenteel
-
A randomized phase II clinical trial on intratumoral autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) plus ipilimumab (IPI) and synthetic adjuvant AS01B combined with low-dose intravenous (IV) nivolumab (NIVO) in advanced pretreated melanoma patients.
Bertels, C., Dirven, I., Vounckx, M., Van Riet, I., De Becker, A. & Neyns, B., 1 jun. 2026, In: Journal of Clinical Oncology. 44, 16_SUPPL, blz. 21514-21514 1 blz., e21514.Onderzoeksoutput: Meeting abstract (Journal)
-
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases
Mandalà, M., Chen, M. F., Sullivan, R. J., Sergi, M. C., Postow, M., Lawless, A. R., Effiom, D., Peres, T., Lorigan, P. C., Serra-Bellver, P., Dummer, R., Amaral, T., Rasch, M.-L., Giannarelli, D., Vitale, M. G., Helgadottir, H., Robert, C., Ubaldi, M., Johnson, D. B. & Del Vecchio, M. & 25 anderen, , 4 mei 2026, In: Journal for ImmunoTherapy of Cancer. 14, 5, 12 blz., e015063.Onderzoeksoutput: Article › peer review
Open Access -
Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial
Dirven, I., Bertels, C., Moreels, Y., Kessels, J. I., Vanlaer, N., Vander Mijnsbrugge, A.-S., Vounckx, M., Dirks, I., Raes, L., Geeraerts, X., Stevens, L., von Kemp, B., Fasolino, G., Awada, G., Janssen, T., Caljon, B., Lefevre, T., Everaert, H., Rogiers, A. & Vandemeulebroucke, J. & 2 anderen, , apr. 2026, In: ESMO Open. 11, 4, 11 blz., 106941.Onderzoeksoutput: Article › peer review
Open Access -
Erratum to: Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma
Duerinck, J., Lescrauwaet, L. & Dirven, I., 1 apr. 2026, In: Neuro-oncology. 28, 4, blz. e2-e2 1 blz.Onderzoeksoutput: Article › peer review
Open Access -
Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrative Review
Vounckx, M., Dirven, I., Bertels, C., Schwarze, J. K., Geeraerts, X., Tuyaerts, S., Boisson, A., Willard-Gallo, K. & Neyns, B., 30 apr. 2026, In: Vaccines. 14, 5, 15 blz., 402.Onderzoeksoutput: Scientific review › peer review
Open Access
Prijzen
-
Bestand
Activiteiten
-
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma (NEO-GLITIPNI).
Dirven, I. (Speaker)
31 mei 2025Activiteit: Talk or presentation at a conference
-
Management of patients with melanoma central nervous system metastases
Dirven, I. (Speaker)
18 okt. 2025Activiteit: Talk or presentation at a conference
-
2025 ASCO Annual Meeting
Aspeslagh, S. (Participant), Cleo, B. (Participant), Dirven, I. (Participant) & Decoster, L. (Participant)
30 mei 2025 → 3 jun. 2025Activiteit: Participation in conference
-
ASCO
Neyns, B. (Participant), Joris, S. (Participant), Dirven, I. (Participant), Kessels, J. (Participant) & Decoster, L. (Chair)
31 mei 2024 → 4 jun. 2024Activiteit: Participation in conference
-
Melanoma treatment Anno 2024
Dirven, I. (Speaker)
9 mrt. 2024Activiteit: Talk at a public lecture/debate